SLC2A3 and neoplasm: First, in comparing the tumor size of mice treated with sorafenib and with and without overexpression of either OSGIN-1 or SLC2A3, Deng et al. (2025) observed the smallest tumor size in OSGIN-1 overexpression mice treated with sorafenib.